Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency

References

• Blanco I, de Serres FJ, Carcaba V, et al. Alpha-1 antitrypsin deficiency PI*Z and PI*S gene frequency distribution using on maps of the world by an inverse distance weighting (IDW) multivariate interpolation method. Hepat Mon 2012; 12(10 HCC):e7434.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168(7):818–900.
   PubMed Web of Science ®Google Scholar
• Janciauskiene SM, Bals R, Koczulla R, et al. The discovery of alpha1-antitrypsin and its role in health and disease. Respir Med 2011; 105(8):1129–1139.
   PubMed Web of Science ®Google Scholar
• Bernspång E, Sveger T, Piitulainen E. Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency. Respir Med 2007; 101(9):1971–1976.
   PubMed Web of Science ®Google Scholar
• Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax 2004; 59(5):441–445.
   Google Scholar
• Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med 1994; 61(6):461–467.
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350(26):2645–2653.
   PubMed Web of Science ®Google Scholar
• McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 2011; 365(17):1567–1575.
   PubMed Web of Science ®Google Scholar
• Halpin DM, Tashkin DP. Defining disease modification in chronic obstructive pulmonary disease. COPD 2009; 6(3):211–225.
   PubMedGoogle Scholar
• Chapman KR, Burdon JGW, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386:360–368.
   PubMed Web of Science ®Google Scholar
• Bespalov A, Klein C, Behl B, et al. Development of disease-modifying treatment of schizophrenia. Handb Exp Pharmacol 2012; 213:419–442.
   PubMedGoogle Scholar
• Cummings JL. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers Dement 2006; 2(4):263–271.
   PubMedGoogle Scholar
• Köhnlein T, Welte T. Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Am J Med 2008; 121(1):3–9.
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Pennycooke K, Carroll TP, et al. The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease. COPD 2015; 12 Suppl 1:2–9.
   PubMedGoogle Scholar
• Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981; 68(5):1158–1165.
   Google Scholar
• Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316(17):1055–1062.
   PubMed Web of Science ®Google Scholar
• Wewers MD, Crystal RG. Alpha-1 antitrypsin augmentation therapy. COPD 2013; 10 Suppl 1:64–67.
   PubMedGoogle Scholar
• Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118(5):1480–1485.
   PubMed Web of Science ®Google Scholar
• The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 1998; 158(1):49–59.
   PubMed Web of Science ®Google Scholar
• Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10(10):2260–2263.
   PubMed Web of Science ®Google Scholar
• Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160(5 Pt 1):1468–1472.
   PubMed Web of Science ®Google Scholar
• Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33(6):1345–1353.
   PubMed Web of Science ®Google Scholar
• Bhattaram VA, Siddiqui O, Kapcala LP, Gobburu JV. Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. AAPS J 2009; 11(3):456–464.
   PubMed Web of Science ®Google Scholar
• D'Agostino RB, Sr. The delayed-start study design. N Engl J Med 2009; 361(13):1304–1306.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328(3):176–183.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361(13):1268–1278.
   PubMed Web of Science ®Google Scholar
• Vellas B, Andrieu S, Sampaio C, et al. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 2008; 7(5):436–450.
   PubMed Web of Science ®Google Scholar
• Vellas B, Andrieu S, Sampaio C, et al. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 2007; 6(1):56–62.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA). Guidance for industry—Alzheimer's disease: developing drugs for the treatment of early stage disease. Available from: http://wwwfdagov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287pdf (published February 2013, accessed April 2016).
   Google Scholar
• U.S. Food and Drug Administration (FDA). Critical path opportunities list. Available from: http://wwwfdagov/downloads/Science-Research/SpecialTopics/CriticalPathInitiative/CriticalPathOpport-unitiesReports/UCM077258pdf (published March 2006, accessed April 2016).
   Google Scholar
• Turino GM, Lin YY, He J, et al. Elastin degradation: an effective biomarker in COPD. COPD 2012; 9(4):435–438.
   PubMedGoogle Scholar
• Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013; 42(3):636–646.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011; 365(13):1184–1192.
   PubMed Web of Science ®Google Scholar
• Faner R, Tal-Singer R, Riley JH, et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax 2014; 69(7):666–672.
   PubMed Web of Science ®Google Scholar
• Coxson HO, Dirksen A, Edwards LD, et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respir Med 2013; 1(2):129–136.
   PubMed Web of Science ®Google Scholar
• Wilke S, Jones PW, Mullerova H, et al. One-year change in health status and subsequent outcomes in COPD. Thorax 2015; 70(5):420–425.
   PubMed Web of Science ®Google Scholar
• Mullerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest 2015; 147(4):999–1007.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 2008; 31(4):869–873.
   PubMed Web of Science ®Google Scholar
• Rennard SI. Chronic obstructive pulmonary disease: linking outcomes and pathobiology of disease modification. Proc Am Thorac Soc 2006; 3(3):276–280.
   PubMedGoogle Scholar
• Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA 1994; 272(19):1497–1505.
   Google Scholar
• Zuwallack RL, Nici L. Modifying the course of chronic obstructive pulmonary disease: looking beyond the FEV1. COPD 2012; 9(6):637–648.
   PubMedGoogle Scholar
• Chapman KR, Stockley RA, Dawkins C, et al. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 2009; 6(3):177–184.
   PubMedGoogle Scholar
• Shaw JG, Vaughan A, Dent AG, et al. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). J Thorac Dis 2014; 6(11):1532–1547.
   PubMed Web of Science ®Google Scholar
• Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res 2010; 11:79.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8):775–789.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• Celli BR. Predictors of mortality in COPD. Respir Med 2010; 104(6):773–779.
   PubMed Web of Science ®Google Scholar
• de Torres JP, Casanova C, Marin JM, et al. Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax 2014; 69(9):799–804.
   PubMed Web of Science ®Google Scholar
• Celli BR. Change in the BODE index reflects disease modification in COPD: lessons from lung volume reduction surgery. Chest 2006; 129(4):835–836.
   PubMed Web of Science ®Google Scholar
• Imfeld S, Bloch KE, Weder W, Russi EW. The BODE index after lung volume reduction surgery correlates with survival. Chest 2006; 129(4):873–878.
   PubMed Web of Science ®Google Scholar
• Stolk J, Putter H, Bakker EM, et al. Progression parameters for emphysema: a clinical investigation. Respir Med. 2007; 101(9):1924–1930.
   PubMed Web of Science ®Google Scholar
• Parr DG, Dirksen A, Piitulainen E, et al. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency. Respir Res 2009; 10:75.
   PubMed Web of Science ®Google Scholar
• Parr DG, Stoel BC, Stolk J, Stockley RA. Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency. Thorax 2006; 61(6):485–490.
   PubMed Web of Science ®Google Scholar
• Stockley RA, Parr DG, Piitulainen E, et al. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010; 11:136.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration (FDA). Clinical and surrogate endpoints for evaluating efficacy of alpha1-proteinase inhibitor (human) augmentation therapy. Blood Products Advisory Committee 95th Meeting July 20–21, 2009. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmater-ials/bloodvaccinesandotherbiologics/bloodproductsadvisory-committee/ucm171091.pdf (accessed April15 2016).
   Google Scholar
• Craig TJ. Suspecting and testing for Alpha-1 antitrypsin deficiency—an allergist's and/or immunologist's perspective. J Allergy Clin Immunol Pract 2015; 3(4):506–511.
   Web of Science ®Google Scholar
• Wielputz MO, Bardarova D, Weinheimer O, et al. Variation of densitometry on computed tomography in COPD—influence of different software tools. PLoS One 2014; 9(11):e112898.
   Google Scholar
• Dawkins PA, Dowson LJ, Guest PJ, Stockley RA. Predictors of mortality in alpha1-antitrypsin deficiency. Thorax 2003; 58(12):1020–1026.
   PubMed Web of Science ®Google Scholar
• Kohnlein T, Janciauskiene S, Welte T. Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency. Ther Adv Respir Dis 2010; 4(5):279–287.
   PubMedGoogle Scholar
• Wozniak J, Wandtke T, Kopinski P, Chorostowska-Wynimko J. Challenges and prospects for alpha-1 antitrypsin deficiency gene therapy. Hum Gene Ther 2015; 26(11):709–718.
   PubMed Web of Science ®Google Scholar
• Muñiz-Hernández S, Hernández-Pedro N, Macedo-Pérez OE, Arrieta O. Alterations in retinoic acid receptors in non-small cell lung cancer and their clinical implications. J Cancer Ther 2015; 6:648–664.
   Google Scholar
• Stolk J, Stockley RA, Stoel BC, et al. Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor. Eur Respir J 2012; 40(2):306–312.
   PubMed Web of Science ®Google Scholar
• Belloni PN, Garvin L, Mao CP, et al. Effects of all-trans-retinoic acid in promoting alveolar repair. Chest 2000; 117(5 Suppl 1):235S–241S.
   Google Scholar
• Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 1997; 3(6):675–677.
   PubMed Web of Science ®Google Scholar
• Hidvegi T, Ewing M, Hale P, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010; 329(5988):229–232.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Carbamazepine in Severe liver disease due to alpha-1 antitrypsin deficiency. Available from: https://clinicaltrials.gov/ct2/show/NCT01379469 (published February 2016, accessed April 2016).
   Google Scholar
• Guo S, Booten SL, Aghajan M, et al. Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice. J Clin Invest 2014; 124(1):251–261.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. A study of ARC-AAT in healthy volunteer subjects and patients with alpha-1 antitrypsin deficiency (AATD). Available from: https://clinicaltrials.gov/ct2/show/NCT02363946 (published July 2015, accessed April 2016).
   Google Scholar
• Mahler DA, Criner GJ. Assessment tools for chronic obstructive pulmonary disease: do newer metrics allow for disease modification? Proc Am Thorac Soc 2007; 4(7):507–511.
   PubMedGoogle Scholar